Reslizumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 468 publications
Biologics in severe asthma: from precision phenotyping to clinical remission.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: March 14, 2026
Depemokimab (Exdensur) for severe eosinophilic asthma.
Journal: The Medical letter on drugs and therapeutics
Published: March 07, 2026
Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR).
Journal: Allergy, asthma & immunology research
Published: February 21, 2026
Current and Emerging Biologic Therapies for Severe Asthma.
Journal: Drugs
Published: February 07, 2026
Comparative analysis of the manufacturing carbon footprint of biologics for severe asthma.
Journal: BMJ open
Published: January 07, 2026
A review of the safety of antibody therapy in severe eosinophilic asthma.
Journal: Expert review of respiratory medicine
Published: December 18, 2025
Biologic therapies for severe pediatric asthma: efficacy, safety, and biomarker-guided selection.
Journal: Frontiers in allergy
Published: November 30, 2025
Glucocorticoid Treatment in Severe Asthma.
Journal: Seminars in respiratory and critical care medicine
Published: November 14, 2025
Rapid Desensitization to Reslizumab in an 80-Year-Old Woman With Chronic Eosinophilic Pneumonia, Severe Persistent Asthma, and Chronic Urticaria.
Journal: Cureus
Published: November 11, 2025
The Impact of BMI on the Effect of Biologic Agents for Severe Asthma.
Journal: Pulmonary therapy
Published: November 01, 2025
Using biomarkers and independent predictors of therapy response to optimize treatment of uncontrolled severe asthma in the biologic era.
Journal: Frontiers in allergy
Published: October 07, 2025
Last Updated: 04/28/2026